Therapeutic Class


Eastern and Western Encephalomyelitis (Sleeping Sickness), Equine Influenza Vaccine and Tetanus Toxoid

A combination of inactivated, purified, concentrated, adjuvanted, tissue culture origin, Eastern and Western Equine Encephalomyelitis Viruses,, Equine Influenza Virus subtypes A2 including KY 93, KY 02, and NM2/93 strains, and Tetanus Toxoid. Merck Animal Health serological data suggest cross protection against certain U.S. and European strains, including Kentucky 91, 93, 99, 02, Ohio 03, Newmarket1/93, Newmarket 2/93, Suffolk 89, and South Africa 03.

For vaccination of healthy horses, 6 months of age or older, as an aid in the prevention of Eastern and Western Encephalomyelitis and Tetanus, and as an aid in the reduction of virus shedding and control of respiratory disease caused by Equine Influenza Virus. Duration of Immunity (DOI) has been shown to be at least 6 months for Influenza. Foals nursing immune-dams should be vaccinated when naternal antibody levels will allow active immunization.

Administration and Dosage
For primary immunization, aseptically inject 1 mL intramuscularly and repeat the dose in 3 to 4 weeks. Annual revaccination is recommended. A booster dose can be administered at more frequent intervals based upon individual horse or farm disease risk assessment or any time ep8idemic conditions exist or are reported. Consult your veterinarian.

Store at 35o to 45o (2o to 7o C). Shake well before using. Do not vaccinate within 21 days before slaughter. Local reactions may occur if this product is given subcutaneously. Inject deep into the muscle only. Anaphylactoid reactions may occur.

Epinephrine. Neomycin, polymyxin B and nystatin added as preservatives.

Code: 035127
10 X 1 mL (1 dose) sterile syringes per box, individually printed plastic bag with needle.
Code: 031685
10mL (10 doses)vial.

Product Label(s) and MSDS

For more information about Merck Animal Health Products call 1-800-441-8272.